

SPONSOREN

**Boston
Scientific**

Abbott

Medtronic

Alnylam
PHARMACEUTICALS

AtriCure

BAYER

**Boehringer
Ingelheim**

Pfizer

AstraZeneca

BIOTRONIK
excellence for life

Bristol Myers Squibb

Daichi-Sankyo

Edwards

NOVARTIS

novo nordisk

sanofi

Sponsoring: Boston Scientific Medizintechnik GmbH EUR 70.000 | Medtronic GmbH EUR 20.000 | Abbott GmbH EUR 10.000 | Alnylam Germany GmbH EUR 5.000 | AtriCure EUR 5.000 | Bayer Vital GmbH EUR 5.000 | Boehringer Ingelheim Pharma GmbH & Co. KG EUR 5.000 | Pfizer Pharma GmbH EUR 5.000 | Bristol-Myers Squibb GmbH & Co. KGaA EUR 3.000 | AstraZeneca GmbH EUR 2.000 | Daichi Sankyo Deutschland GmbH EUR 2.000 | BIOTRONIK SE & Co. KG EUR 1.500 | Edwards Lifesciences GmbH EUR 1.500 | Novartis Pharma GmbH EUR 1.000 | Novo Nordisk Pharma GmbH EUR 1.000 | Sanofi-Aventis Deutschland GmbH EUR 1.000

Die Veranstalter und Referenten bestätigen die Produktneutralität des Programms und der Vorträge. Die Darstellung möglicher Interessenkonflikte erfolgt vor dem Vortrag.

SCHIRMHERRSCHAFTEN

AFNET
EV

DGK
Schirmherrschaft

TAGUNGSHOTEL

RADISSON BLU HOTEL
FRANKLINSTRASSE 65
60486 FRANKFURT AM MAIN



ANMELDUNG

**Kostenfreie Teilnahme vor Ort
und online möglich!**

medpoint.de



**8
CME-PUNKTE
ERWARTET**

Scientific Program Directors
PROF. DR. REZA WAKILI
PROF. DR. DOBROMIR DOBREV

Live-Stream und Simultanübersetzung per Audio



FRANKFURT
2026
27.05.2026

SKY AF
Summit

Radisson Blu Frankfurt &
Live-Stream

INVITATION

We are delighted to welcome you to the Sky AF Summit Frankfurt, an international scientific meeting dedicated to the latest advances in the understanding and treatment of atrial fibrillation (AF). The program brings together leading experts in clinical cardiology, electrophysiology, and cardiac surgery to explore new data, evolving technologies, and translational insights that are shaping the next era of AF management.

Discussions will cover the full therapeutic spectrum – from oral anticoagulation and stroke prevention to novel ablation techniques, hybrid strategies, and future directions in device-based therapy. In addition, sessions will focus on comorbidities such as heart failure, metabolic disorders, and renal dysfunction, emphasizing their impact on patient outcomes.

Through scientific exchange, live case sessions, and interactive debates, the Sky AF Summit aims to bridge evidence and experience, connecting innovative research with everyday clinical practice.

PROGRAM | 27.05.2026

08.45 am **PROF. DR. REZA WAKILI & PROF. DR. DOBROMIR DOBREV**

09.00 – 10.20 am TRANSLATIONAL INSIGHTS INTO AF MECHANISMS

Chair: Prof. Dr. Dobromir Dobrev | Prof. Dr. Dominik Linz
Panel Discussion: Prof. Dr. Joachim Ehrlich | Prof. Dr. Constanze Schmidt

Role of Atrial Cardiomyocyte Inflammatory Signaling
PROF. DR. DOBROMIR DOBREV Universitätsmedizin Essen

Genetics – Lessons Learned and Current Implications
PROF. DR. STEFAN KÄÄB LMU Klinikum

Role of Large Animal Models and In-Vitro Experiments
PROF. DR. CONSTANZE SCHMIDT Universitätsmedizin Göttingen

Role of Mitochondrial Dysbalance
PROF. DR. NIELS VOIGT Universitätsmedizin Göttingen

AF & HFrefEF – Translational View on Mechanisms and Therapy
DR. ANDREAS BÖHMER Universitätsmedizin Frankfurt

10.20 – 11.20 am STROKE PREVENTION IN AF – PART I

Chair: Prof. Dr. Thorsten Lewalter | Prof. Dr. Reza Wakili
Panel Discussion: Prof. Dr. Lars Eckardt

Oral Anticoagulation in 2026 – Real-World Perspectives on Factor Xa & XI Inhibitors
PD DR. JULIA ERATH-HONOLD Universitätsmedizin Frankfurt

Role of AHREs – Who Benefits Most From Oral Anticoagulation?
PROF. DR. PAULUS KIRCHHOF Universitätsklinikum Hamburg-Eppendorf

Oral Anticoagulation After Successful PVI – Still Required?
PROF. DR. ANDREAS METZNER* Universitätsklinikum Hamburg-Eppendorf

Epidemiology of AF – what do we know, what do we need to know?
PROF. DR. RENATE BONIN-SCHNABEL Universitätsklinikum Hamburg-Eppendorf

11.20 am Coffee Break and Industry Exchange

11.45 am – 01.00 pm NOVEL DRUG THERAPIES IN AF BEYOND OAC AND PVI

Chair: Prof. Dr. Paulus Kirchhof | Prof. Dr. Constanze Schmidt
Panel Discussion: Prof. Dr. Dobromir Dobrev | Prof. Dr. Joachim Ehrlich | Prof. Dr. Niels Voigt

Role of Novel Antiarrhythmic Drugs
PROF. DR. JOSÉ LUIS MERINO LLORENS La Paz University Hospital, Madrid/Spain

Role of Traditional Antiarrhythmic Drugs
PROF. DR. LARS ECKARDT Universitätsklinikum Münster

Obesity and Metabolic Syndrome
DR. VICTORIA JOHNSON Universitätsmedizin Frankfurt

AF Therapy in HOCM and Amyloidosis
PD DR. MARIA PAPATHANASIOU Universitätsmedizin Frankfurt

Chronic Kidney Disease and AF – Role of SGLT2 Inhibitors and MRAs
TBD

01.00 pm Lunch Break and Industry Exchange

01.45 – 03.00 pm STROKE PREVENTION IN AF – PART II

Chair: Prof. Dr. Jeff S. Healey | Prof. Dr. Arian Sultan
Panel Discussion: Prof. Dr. Lars Eckardt | Prof. Dr. Reza Wakili

LAAO – Closure AF
DR. SEBASTIAN HABERKORN Universitätsmedizin Frankfurt

OPTION Trial
PROF. DR. THORSTEN LEWALTER Osypka Herzzentrum München

CHAMPION
PROF. DR. REZA WAKILI Universitätsmedizin Frankfurt

Optimal Choice and Regime of Anticoagulation After LAAO
PROF. DR. BORIS SCHMIDT MVZ CCB Frankfurt und Main-Taunus

Outlook 2027 – LAAOS IV and What Else Is Coming and Needed
PROF. DR. JEFF S. HEALEY McMaster University, Hamilton/Kanada

03.00 – 04.15 pm SURGERY MEETS CARDIOLOGY IN AF TREATMENT

Chair: Prof. Dr. David M. Leistner | Prof. Dr. Thomas Walther
Panel Discussion: Prof. Dr. Armin Luik | PD Dr. Philipp Seppelt | Prof. Dr. Daniel Steven

Epicardial PVI + LAAO – The Surgeon's View
PROF. DR. NICOLAS DOLL Schüchtermann-Klinik Bad Rothenfelde

Endocardial PVI + LAAO – The Electrophysiologist's View
PROF. DR. ARIAN SULTAN Asklepios Kliniken Hamburg

Mitral Valve Repair Combined With PVI and LAAO
DR. FABIAN EMRICH Universitätsmedizin Frankfurt

PVI ± LAAO After mTEER
PROF. DR. DANIEL STEVEN Uniklinik Köln

LIAB: PFA-PVI + LAAO (FARAWAVE + WATCHMAN With VersaCross)
PROF. DR. REZA WAKILI & DR. SEBASTIAN HABERKORN Universitätsmedizin Frankfurt

04.15 pm Coffee Break and Industry Exchange

04.40 – 05.40 pm MAPPING AND ABLATION WITH PFA

Chair: Prof. Dr. Philipp Sommer | Prof. Dr. Reza Wakili
Panel Discussion: Prof. Dr. Armin Luik | PD Dr. Obaida Rana | Prof. Dr. Christian Sohns

Focal PFA – For Which Arrhythmia?
PD DR. OBAIDA RANA Universitätsklinikum Düsseldorf

PVI+ With PFA-Integrated 3D Mapping – Overview
PROF. DR. PHILIPP SOMMER Herz- und Diabeteszentrum Nordrhein-Westfalen

LIAB: PVI „+“ PFA Single-Shot integrated in 3D Mapping
DR. ANASTASIA FALAGKARI Universitätsmedizin Frankfurt

LIAB: AFFERA – Re-Do Ablation With Sphere-9 & PVI-only With Sphere-360
PD DR. LAURA ROTTNER Universitätsmedizin Frankfurt

05.40 – 06.50 pm PVI IN HFrefEF, HFmREF, HFpEF – OR ALL HFpAF?

Chair: Prof. Dr. Nassir F. Marrouche | Prof. Dr. Andreas Metzner*
Panel Discussion: Dr. Melanie Gunawardene | Prof. Dr. Thorsten Lewalter | PD Dr. Laura Rottner

HFrefEF
PROF. DR. CHRISTIAN SOHNS Herz- und Diabeteszentrum Nordrhein-Westfalen

HFpEF
PD DR. ABDUL SHOKOR PARWANI Deutsches Herzzentrum der Charité (DHZC)

HFxEF – What Trials are Required for the Future?
PROF. DR. NASSIR F. MARROUCHE Tulane University Heart & Vascular Institute, New Orleans/USA

HOCM and Amyloidosis: Role of Single Shot PFA-PVI
PROF. DR. PATRICK LUGENBIEL Universitätsklinikum Heidelberg

Role of AF Burden vs. Freedom From AF in HF&AF
PROF. DR. JASON G. ANDRADE* The University of British Columbia, Vancouver/Kanada

06.50 – 07.00 pm SUMMARY

PROF. DR. REZA WAKILI Universitätsmedizin Frankfurt
PROF. DR. DOBROMIR DOBREV Universitätsmedizin Essen

07.00 – 08.00 pm MEET THE EXPERTS IN THE SPEAKERS' CORNER

08.00 pm Adjournment

*to be confirmed